Approved Weight-Loss Options May Already Help Retatrutide is still in trials, but patients can start improving their health now
As we navigate an obesogenic environment and confront obesity as a complex disease, the continued development of therapeutics that target gut peptides and taste receptors will undoubtedly play a major role in the future of metabolic medicine
In vitro evidence suggests that caffeine can inhibit the metabolism of flutamide
Individual response varies based on medication formulation, baseline metabolic status, adherence to lifestyle modifications, and gastrointestinal tolerance
GLP1-RAs currently available in Canada include semaglutide (Ozempic, Ryblesus, Wegovy), liraglutide (Victoza, Saxenda, Xultophy ), dulaglutide (Trulicity), lixisenatide (Soliqua ) and tirzepatide (Mounjaro, Zepbound)
Listen to our podcast episode in full below or on your preferred streaming platform